Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
(Date:12/20/2014)... Parker & Sons, Inc. a focused ... experience in contractor services announces reaching a milestone by ... homeowners of Arizona. Parker and Sons is comprised of ... that make customer service the number one priority. The ... started with one service vehicle and has since grown ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... 2014 Energy Textiles is excited ... available. Celliant, the world’s leading responsive textile, can ... , There are a number of benefits to ... oxygenation and balanced body temperature; which can lead ... relief; enhanced athletic performance; and overall wellness. In ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... December 20, 2014 An evening dress is ... a lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled ... beautiful dresses in this great shopping platform. Customers can ... the staff's hard work, Discount-Dress.com has been accepted and praised ... faster and easier shopping stage for clients. In order to ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2
... also Establishes New Site Leadership Team at Cambridge ... Continuing the,solidification of its role as the global ... that Andrew D. Skibo has joined the company,as ... a 19-year,veteran of the company, has been promoted ...
... Philadelphia, PA, December 20, 2007 For U.S. veterans ... health functioning are associated with an increased risk of ... of the journal General Hospital Psychiatry. , "Our findings ... for mental health functioning as a risk factor and ...
... tests, so have advanced disease , , THURSDAY, Dec. 20 ... have health insurance are more likely to die because ... so are typically diagnosed with advanced disease, a new ... finding proffers strong evidence that differences in cancer survival ...
... WOODCLIFF LAKE, N.J., Dec. 20 Par,Pharmaceutical Companies, Inc. ... and Exchange Commission (SEC) its Form 10-Q for the ... for this period had been,delayed due to the work ... periods, which were filed earlier this year.,As a result ...
... Exchange Symbol: AKL, MONTREAL, Dec. 20 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation and ... market,conditions, particularly in the small and micro-cap sector, ... initiative. The Company is currently,contemplating other financing options. ...
... Data Show PROMACTA Significantly Raised Platelet Counts and,Lowered ... Treatment of,Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP), ... GSK ; London) today announced the submission ... States Food and Drug Administration,(FDA) for approval to ...
Cached Medicine News:Health News:MedImmune Expands Scientific and Engineering Leadership 2Health News:MedImmune Expands Scientific and Engineering Leadership 3Health News:MedImmune Expands Scientific and Engineering Leadership 4Health News:MedImmune Expands Scientific and Engineering Leadership 5Health News:Mental health linked to amputation risk in diabetic veterans 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 2Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 3Health News:Uninsured More Likely to Die From Cancer Following Diagnosis 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 2Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 3Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 4Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 5Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 6Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 7Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 8Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 9Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 10Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 11Health News:Par Pharmaceutical Reports Third-Quarter 2007 Results 12Health News:Akela Pharma provides corporate update 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 2Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 3Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 4Health News:GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder 5
Porous foundation 440 series....
A cementless femoral stem that promotes bone in-growth and reduces thigh pain....
The cemented hip joint prosthesis system....
The uncemented hip joint prosthesis system...
Medicine Products: